"Glacia" is produced from the plasma of healthy people, and reduces the need for lung transplantation in patients with a rare disease most often caused by smoking. Kamhada, which manufactures the drug in Kibbutz Negev, submitted it to the 2022 drug basket, after passing FDA and Ministry of Health approval, at an estimated cost of NIS 4 million.
The main cause of chronic obstructive pulmonary disease, also called COPD, is heavy smoking, but in a small proportion of patients (1% -3%), the disease is caused by a genetic deficiency in an essential protein called alpha 1, whose function is to protect the lungs from damage and infection. In these patients, an ongoing and irreversible process of lung tissue destruction takes place, from a relatively young age. Diagnosis of protein deficiency is determined through a series of tests, including a genetic test.
Blue and white breakthrough: A new Israeli drug will increase the life expectancy of lung patients
Walla! News 17.08.2021
Did you find this article interesting?
Comments
To leave a comment, please log in
Subscribe to our Newsletter